Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02153580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
NotablePrimary and study completion pushed from Sep 2, 2026 to Aug 11, 2027Interventions: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (Biological), Bendamustine Hydrochloride (Drug)… to Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (Biological), Bendamustine Hydrochloride (Drug)… · Eligibility criteria expanded, about 33 words · Secondary endpoints: details revised at 2 of 3 entries · 2 moreShow 5 more changesShow less
Secondary endpoints: details revised at 2 of 3 entries
Study description revised
Publications: details revised at 1 of 1 entry
NotablePrimary and study completion dates: Sep 16, 2025 to Sep 2, 2026v26
NotablePrimary completion date: Dec 30, 2024 to Sep 16, 2025Completion date: Dec 31, 2024 to Sep 16, 2025v25Show 1 more changeShow less
Completion date: Dec 31, 2024 to Sep 16, 2025
NotablePrimary completion date: Dec 30, 2023 to Dec 30, 2024Completion date: Dec 31, 2023 to Dec 31, 2024v24Show 1 more changeShow less
Completion date: Dec 31, 2023 to Dec 31, 2024
NotablePrimary completion date: Jun 30, 2023 to Dec 30, 2023v23
Show 21 earlier versionsHide 21 earlier versions
NotablePrimary completion date: Jun 30, 2022 to Jun 30, 2023Completion date: Dec 31, 2022 to Dec 31, 2023v22Show 1 more changeShow less
Completion date: Dec 31, 2022 to Dec 31, 2023
NotablePrimary completion date: Dec 31, 2021 to Jun 30, 2022Enrollment target: estimated 54 to confirmed 37 · Completion date: Dec 31, 2021 to Dec 31, 2022v21Show 2 more changesShow less
Enrollment target: estimated 54 to confirmed 37
Completion date: Dec 31, 2021 to Dec 31, 2022
MinorEnrollment target: 48 to 54Interventions: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (Biological), Bendamustine Hydrochloride (Drug), Etoposide… to Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (Biological), Bendamustine Hydrochloride (Drug)… · Eligibility criteria expanded, about 82 words · Secondary endpoints revised (3) · 3 morev20Show 6 more changesShow less
MinorTrial status: Recruiting to Active, Not RecruitingPrimary and study completion dates: Dec 2021 to Dec 31, 2021 · Site details revisedv19Show 2 more changesShow less
Primary and study completion dates: Dec 2021 to Dec 31, 2021
NotablePrimary and study completion dates: Dec 2018 to Dec 2021Interventions: Bendamustine Hydrochloride (Drug), Etoposide (Drug), Fludarabine Phosphate (Drug), autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing… to Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (Biological), Bendamustine Hydrochloride (Drug), Etoposide… · Eligibility criteria expanded, about 277 words · Secondary endpoints: details revised at 1 of 3 entries · 2 morev15Show 5 more changesShow less
NotableTrial status: Active, Not Recruiting to RecruitingPrimary and study completion dates: Sep 2018 to Dec 2018 · Site details revisedv14Show 2 more changesShow less
Primary and study completion dates: Sep 2018 to Dec 2018
Site details revised
MinorRe-verified, no change to tracked fieldsv13
NotablePrimary completion date: Sep 2017 to Sep 2018Completion date: Sep 2018 · Start date: Sep 2014 to Sep 24, 2014v12Show 2 more changesShow less
Completion date: Sep 2018
Start date: Sep 2014 to Sep 24, 2014
Minor2 versionsRe-verified since Jan 28, 2016, no change to tracked fieldsv10-v11
MinorTrial status: Recruiting to Active, Not RecruitingSite details revisedv9Show 1 more changeShow less
Site details revised
NotablePrimary endpoints revised (2)Eligibility criteria expanded, about 93 words · Study title revisedv8Show 2 more changesShow less
MinorInterventions: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (Biological), cyclophosphamide (Drug), laboratory biomarker analysis… to Bendamustine Hydrochloride (Drug), Etoposide (Drug), Fludarabine Phosphate (Drug), autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing…Eligibility criteria expanded, about 35 words · Study description expanded, about 74 wordsv7Show 2 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingSite details revisedv2Show 1 more changeShow less
Site details revised
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.